Carsten Thiel has a Ph.D and was the CEO of Abeona Therapeutics Inc. This is a biopharmaceutical company for clinical-stages that mainly develops gene and cell therapies for genetic diseases that are rare and life-threatening. It is a company that is a major part of the golden age of biotechnology that Carsten Thiel is very much a part of.
An article with Globe Newswire, “Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer”; says that the company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases.
According to Carsten Thiel, entering the “Golden Age of Biotechnology” is quite profound and beneficial to the implications for humanity. It is now possible to address the most basic type of human concerns which are staying free of disease, having a healthier life and being able to live longer.
Technology is now a major part in the industries of health that are so advanced that it has increased the speed of new discoveries and innovation both in exponential and non-linear manners. These advantages are attributed to the speed of technological progress.
Carsten Thiel has been able to contribute to this progress. Another factor is that there is a much better understanding of human biology. This is able to be achieved by using a larger toolkit. There are now over a dozen various modalities that can be engineered to use to interdict any targets that are biological. Laser focusing, nanoparticle delivery systems, gene therapy, and regenerative cell therapies are only a few examples of the new modalities that can help treat a rare disease. See Related Link for additional information.
Even though some may speculate that there can be no more advances in biotechnology, there are those who say that it has a golden future.